

Hypoxia-Selective Antitumor Agents. 9. Structure-Activity Relationships for Hypoxia-Selective Cytotoxicity among Analogues of 5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

Brian D. Palmer,[†] William R. Wilson,[‡] Graham J. Atwell,[†] Diane Schultz,[‡] Xing Z. Xu,[‡] and William A. Denny*[†]


Cancer Research Laboratory and Department of Pathology, University of Auckland School of Medicine, Private Bag, Auckland, New Zealand

Received March 2, 1994*

A series of analogues of the novel hypoxia-selective cytotoxin 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (**6**) have been prepared and evaluated, in a search for compounds which retain high hypoxic selectivity but have increased potency and/or aqueous solubility. Several analogues with ionizable or dipolar carboxamide side chains showed improved solubility but generally had reduced cytotoxic potency and hypoxic selectivity. Modification of the mustard leaving groups or replacement of the carboxamide moiety provided some compounds with superior potency, but only the mixed chloro/mesylate mustard **20** provided a gain in potency relative to solubility while retaining the hypoxic selectivity of **6**. These nitrogen mustards did not show the remarkable activity demonstrated by the related aziridine **7** [CB 1954, 5-(*N*-aziridinyl)-2,4-dinitrobenzamide] in Walker 256 adenocarcinoma cells and are not efficient substrates for the DT-diaphorase which activates the latter compound by aerobic nitroreduction in Walker cells. Variations in hypoxic selectivity within the dinitrobenzamide mustards appear not to be due to differences in sensitivity to activation by this enzyme. Walker cells showed intermediate sensitivity to the mono(2-chloroethyl) analogue **26** but not to the related half-mustard **27**, suggesting that the inhibition of DT-diaphorase activity is due to steric effects in the 5-position. The preferred compound overall with respect to solubility, potency, and *in vitro* hypoxic cell selectivity was the (dimethylamino)-ethyl derivative **11**. DNA elution studies and comparison of the sensitivity of AA8 and UV4 cells to this compound indicated reductive activation to form a DNA cross-linking agent under hypoxia. Radiobiological studies indicated **11** to be equally active against both aerobic and hypoxic cells in KHT tumors. It is not clear whether this reflects efficient killing of aerobic cells as a result of diffusion of reduced metabolites from hypoxic regions or whether cytotoxicity in tumors is independent of hypoxia.

There is considerable evidence that hypoxic cells in human tumors can limit the effectiveness of fractionated radiotherapy.¹⁻³ The same cells may also be resistant to many chemotherapeutic drugs.⁴ The development of bioreductive drugs, which are activated to cytotoxic species only in the absence of oxygen (hypoxia-selective cytotoxins, HSCs), is thus of increasing interest, and clinical studies with several compounds [porfiromycin (**1**),⁵ EO-9 (**2**),⁶ RB 6145 (**3**),⁷ and SR 4233 (**4**, tirapazine)⁸] are pending or in progress.

Many bioreductive drugs appear to be fully active only at extremely low oxygen concentrations (<0.1 $\mu\text{M O}_2$).⁹⁻¹¹ Since much higher oxygen concentrations (about 3 μM) are required for half-maximal radiosensitization,¹² it is likely that many hypoxic cells in tumors will be resistant to both radiation and bioreductive drugs.⁹ As we have discussed in detail recently,¹³ this problem might be circumvented by developing HSCs which generate relatively stable cytotoxic products on reduction. If these activated cytotoxins were capable of diffusing several cell diameters (i.e., have half-lives in the range 0.1-10 min), then the killing of relatively well-oxygenated cells surrounding severely hypoxic zones might be achieved. The diffusible cytotoxic species should ideally be effective against all major tumor cell subpopulations (including noncycling cells).




These criteria appear to be met by aliphatic or activated aromatic nitrogen mustards. For example, the 4-aminoaniline mustard **5** is very reactive, with a half-life of ca. 8 min in tissue culture medium at 37 °C,¹⁴ but is capable of effective diffusion into EMT6 tumor spheroids and kills both cycling and noncycling cells efficiently in the tumor-like spheroid microenvironment.¹³ We are therefore interested in the development of bioreductively activated prodrugs of such mustards and have previously discussed nitro-deactivated aniline mustards as HSCs.¹⁵ The reactivity and cytotoxicity of these compounds are very dependent on the electronic properties of the substituents on the aromatic ring;^{14,16} bioreduction of an electron-withdrawing nitro group in a ring position resonant to the mustard (to give the resultant hydroxylamine or amine) is likely to dramatically activate the mustard.

[†] Cancer Research Laboratory.

[‡] Department of Pathology.

* Abstract published in *Advance ACS Abstracts*, June 1, 1994.

Scheme 1^a


^a (i) XNH(CH₂)₂OH/heat; (ii) MsCl/Et₃N, then LiCl; (iii) KOH/dioxane/H₂O; (iv) SOCl₂, then RNH₂.

We have previously shown that the nitro-deactivated mustard 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (6, SN 23862) is 60-fold more potent against anoxic than aerobic Chinese hamster UV4 cells in culture and that this compound is much more selective than the corresponding aziridine 7 (CB 1954).¹⁷ The superiority of 6 over 7 as an HSC has been confirmed in human, rat, and mouse cell lines¹⁸ and has been suggested to result from the lower sensitivity of the mustard, than that of the aziridine, to oxygen-insensitive activation by the obligate 2-electron reductase DT-diaphorase (NAD(P)H:quinone oxidoreductase). The latter enzyme is known to be responsible for aerobic activation of 7 (at least in rat cell lines) by reduction of the 4-nitro group to the hydroxylamine.^{19,20}


Compound 6 is therefore an important new lead for further development. In this paper, we describe the synthesis and the biological evaluation of a series of analogues of 6, seeking compounds which retain the high hypoxic selectivity of the lead compound and will give rise to diffusible cytotoxins on reduction but with increased potency and/or aqueous solubility. In view of the importance of avoiding oxygen-insensitive activation by 2-electron reductases, the compounds were also evaluated for their sensitivity to reduction by rat DT-diaphorase.

Chemistry

Analogues of the lead compound 6 with variations in the carboxamide side chain were conveniently prepared from the acid mustard 21 (Scheme 1). Chloride displacement by diethanolamine from the known²¹ methyl-5-chloro-2,4-dinitrobenzoate (30) gave the diol 31, which was elaborated to the mustard 33 by mesylation and treatment with lithium chloride. Basic hydrolysis then gave the acid 21 in good overall yield, and this was coupled (*via* the acid chloride) with the appropriate amines. A similar route using *N*-ethylethanolamine gave the half-mustards 27 and 28 *via* intermediates 32, 34, and 35 (Scheme 1). Selective oxidation of the *N,N*-dimethylamino group of 11 with 2-(phenylsulfonyl)-3-phenyloxaziridine²² gave the corresponding *N*-oxide 13. Compounds 17–19, with different mustard functionalities, were prepared from the diol 36¹⁷ *via* mesylation and displacement (Scheme 2).

Scheme 2^a

^a (i) MsCl/Et₃N; (ii) NaX; (iii) P₄S₁₀/NaHCO₃; (iv) SOCl₂/reflux; (v) NH(CH₂CH₂OH)₂/heat; (vi) MsCl (2 equiv)/Et₃N/0 °C, then LiCl; (vii) MsCl (4 equiv)/Et₃N/20 °C, then LiCl.

Scheme 3^a

^a (i) *tert*-Bu(Me)₂SiCl/imidazole/DMF/20 °C/18 h; (ii) MsCl/Et₃N/CH₂Cl₂/20 °C/10 min; (iii) LiCl/DMF/125 °C/20 min; (iv) MsCl/THF/20 °C/10 min.

The nitrile 22 was prepared by direct dehydration of 6 in refluxing SOCl₂, while thiation of 6 with P₄S₁₀/NaHCO₃ gave the thioamide 23 (Scheme 2). The benzenesulfonamide 24 was prepared from 5-chloro-2,4-dinitrobenzenesulfonamide²³ (37) by an analogous procedure (formation of the diol 38 with diethanolamine, mesylation, and chloride displacement) (Scheme 2). However, use of an excess of MsCl in this process provided the *N*-(methylsulfonyl)benzenesulfonamide 25 as the major product.

Treatment of the diol 36 with *tert*-butyldimethylsilyl chloride and imidazole in DMF gave a 44% yield of the mono(*tert*-butyldimethylsilyl)oxy derivative 40, together with 38% of the bis(*tert*-butyldimethylsilyl)oxy derivative 39 (Scheme 3). This reagent achieves better selectivity than the high-temperature mesyl chloride reaction reported previously.²⁴ The asymmetric mustard 20 was readily prepared from 40 by mesylation to give 41 followed by chlorination (with concomitant deprotection) on treatment with LiCl in DMF at 120 °C to give the chloride 42 followed by mesylation (Scheme 3).

Table 1. Analytical and Physicochemical Data for Analogues of 5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

no.	X	R	mp (°C)	formula	analyses ^a
6	Cl	CONH ₂	109-111	ref 17	
8	Cl	CONHMe	180.5	C ₁₂ H ₁₄ Cl ₂ N ₄ O ₄	C, H, N, Cl
9	Cl	CONMe ₂	130.5	C ₁₃ H ₁₆ Cl ₂ N ₄ O ₅	C, H, N
10	Cl	COX ^b	140-142	ref 17	
11	Cl	CONH(CH ₂) ₂ NMe ₂ ·HCl	85-90	ref 17	
12	Cl	CONH(CH ₂) ₂ X ^b ·HCl	119-120	C ₁₇ H ₂₃ Cl ₂ N ₅ O ₆ ·HCl	C, H, N, Cl
13	Cl	CONH(CH ₂) ₂ N(O)Me ₂ ·HCl	65-169	C ₁₅ H ₂₁ Cl ₂ N ₅ O ₆ ·HCl	C, H, N, Cl
14	Cl	CONH(CH ₂) ₂ COOH	150-153	C ₁₄ H ₁₆ Cl ₂ N ₄ O ₇	C, H, N
15	Cl	CONHCH ₂ CH ₂ OH	157-158	C ₁₃ H ₁₆ Cl ₂ N ₄ O ₆	C, H, N, Cl
16	Cl	CONHCH ₂ CH(OH)CH ₂ OH	gum	C ₁₄ H ₁₈ Cl ₂ N ₄ O ₇	C, H, N, Cl
17	Br	CONH ₂	126-128	C ₁₁ H ₁₂ Br ₂ N ₄ O ₅	C, H, N
18	I	CONH ₂	170-172 dec	C ₁₁ H ₁₂ I ₂ N ₄ O ₅	C, H, N, I
19	OMe ^c	CONH ₂	142-144	C ₁₃ H ₁₃ N ₄ O ₁₁ S ₂	C, H, N, S
20	Cl/OMe	CONH ₂	103-104	C ₁₂ H ₁₅ ClN ₄ O ₈ S	C, H, N
21	Cl	COOH	125-127	C ₁₁ H ₁₁ Cl ₂ N ₃ O ₆ ·0.5EtOAc	C, H, N
22	Cl	CN	127	C ₁₁ H ₁₀ Cl ₂ N ₄ O ₄	C, H, N
23	Cl	CSNH ₂	166-167	C ₁₁ H ₁₂ Cl ₂ N ₄ O ₄ S	C, H, N, Cl
24	Cl	SO ₂ NH ₂	153-154	C ₁₀ H ₁₂ Cl ₂ N ₄ SO ₆	C, H, N, S
25	Cl	SO ₂ NHSO ₂ Me	206-208	C ₁₁ H ₁₄ Cl ₂ N ₄ S ₂ O ₈ ·0.5H ₂ O	C, H, N, S
26	H	CONH ₂	225	C ₉ H ₉ ClN ₄ O ₅	C, H, N
27	CH ₂ CH ₃	CONH ₂	151-152	C ₁₁ H ₁₃ ClN ₄ O ₅	C, H, N, Cl
28	CH ₂ CH ₃	CONH(CH ₂) ₂ NMe ₂ ·HCl	133-134	C ₁₅ H ₂₂ ClN ₅ O ₅ ·HCl	C, H, N, Cl
7		CONH ₂	189	ref 40	
29		COX ^b	198-200	ref 17	

^a Analyses for all listed elements were within $\pm 0.4\%$. ^b X = morpholide. ^c OMe = OSO₂CH₃.

Biological Evaluation

Aerobic cytotoxicity was assessed in a growth inhibition assay,²⁵ using log-phase cultures of the Chinese hamster ovary fibroblast lines AA8 and UV4. The UV4 mutant derived from AA8 is defective in the repair of bulky DNA monoadducts or cross-links.^{26,27} The ratio of the IC₅₀ values of the compounds in the wild-type and mutant lines can provide evidence for their mode of action; DNA interstrand cross-linking agents show hypersensitivity factors [HF = IC₅₀(AA8)/IC₅₀(UV4)] in the range 8-200-fold.²⁷ DNA cross-linking by compound 11 was also examined using alkaline elution methods.²⁸

Aerobic cytotoxicity against the rat Walker 256 adenocarcinoma was also assessed by growth inhibition assay since this cell line is exquisitely sensitive to 7, being ca. 10⁵-fold more sensitive than Chinese hamster cells,²⁹ primarily because of the efficient activation of this drug by the high levels of DT-diaphorase in Walker cells.^{19,20} The ratio of IC₅₀ values for AA8 and Walker cells was therefore used as an indicator of the sensitivity of these compounds to activation by the Walker cell DT-diaphorase. Reduction of a subset of compounds by highly purified DT-diaphorase from this cell line was also examined by HPLC.

The selective toxicity of the compounds toward hypoxic cells was determined by comparing the rate of killing in aerobic and hypoxic stirred cell suspensions, using a clonogenic assay as described previously.^{25,30} The sensitive UV4 cell line was used, which allowed hypoxic selectivity to be quantitated even for the less soluble analogues. The concentration \times time to reduce the surviving fraction to 10% (CT₁₀) was used as an inverse measure of cytotoxic potency and the ratio of CT₁₀ values under aerobic and

hypoxic conditions as a measure of hypoxic selectivity. The activity of compound 11 against aerobic and hypoxic cells in KHT tumors was assessed by clonogenic assay, using ionizing radiation to kill oxygenated tumor cells and thus reveal the hypoxic subpopulation.

Results and Discussion

The first part of this study focused on close analogues of 6 (compounds 8-16), seeking variations in the carboxamide chain which would provide analogues with better solubility while retaining high selectivity for hypoxic cells in culture. Solubilities were measured in culture medium containing 5% fetal calf serum and are recorded in Table 2. The parent compound 6 has only moderate solubility (0.19 mM), and substituents on the carboxamide in compounds 8-16 provided large variations in this. The CONHMe and CONMe₂ derivatives 8 and 9 were little different from the parent, and the morpholide 10 was even less soluble. The hydroxyethyl derivative 15 was also (unexpectedly) less soluble than the parent, but the dihydroxypropyl compound 16 was 40-fold more soluble. As expected, ionic side chains provided high solubility (compounds 11, 12, and 14), as did the formally neutral but dipolar *N*-oxide group of compound 17. The cytotoxicities of most of these compounds against aerobic AA8 cells in the growth inhibition assay did not differ greatly from that of 6, with the exception of the acid 14 and the *N*-oxide 13 (Table 2). The much lower potencies of these compounds are likely due, at least in part, to low cell uptake. Most of these nitrogen mustards were significantly more active against the UV4 than the AA8 cell line, although wide variations in the HF values were observed (Table 2).

Table 2. Biological Properties of Analogues of 5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

no.	solubility (mM) ^a	aerobic growth inhibition			clonogenic assay (UV4)	
		IC ₅₀ (μM) ^b AA8	IC ₅₀ ratios		hypoxic CT ₅₀ ^e	air/N ₂ ^f
			AA8/Walker ^c	AA8/UV4 (HF) ^d		
6 ^g	0.19	470 ± 50	4.1	6.8 ± 1.1	95 ± 30	58
8	0.20	>100 ^h	<i>i</i>	<i>i</i>	>360 ^h	
9 ^g	0.13	310 ± 40	<0.3	1.4 ± 0.1	250 ± 80	>20
10 ^g	0.03	240 ± 87	4.1	23 ± 5	125 ± 13	1.3 ± 0.3
11	35	220 ± 33	5.6	3.9 ± 0.7	21 ± 4	60 ± 8
12 ^g	4.7	920 ± 430	3.7	3.0 ± 0.1	83	45
13 ^g	>42	7290 ± 1470	2.3	1.7 ± 0.1	4500 ± 600	8
14	11	6100 ± 1040	1.5	1.1 ± 0.1	12 000 ± 3000	2.3 ± 0.3
15	0.10	>100 ^h	<i>i</i>	<i>i</i>	<i>i</i>	
16	7.4	1930 ± 140	1.6	4.4 ± 1.3	465 ± 39	8.6 ± 1.8
17	0.042	57 ± 1	3.1	7.5 ± 1.0	8.0	20
18	0.035	34 ± 2	5.2	2.6 ± 1.1	4.4 ± 0.7	42 ± 2
19	0.53	>200 ^h	>3	>4	70	17
20	0.84	945 ± 90	6.0	13 ± 1	48 ± 3	60
21	18	10 600 ± 500	4.7	1.4 ± 0.1	19 000	>1.2
22	0.12	24 ± 1.4	3.2	6.8 ± 1.0	10 ± 1	8.5 ± 1.5
23	0.038	>25 ^h	>1	>2	19	>3
24	0.16	2.0 ± 0.7	1.7	1.5 ± 0.5	5.7	2.1
25	32	466 ± 75	1.5	1.0 ± 0.1	980 ± 330	5.2
26		748 ± 172	380	1.4 ± 0.4		
27	0.16	>97	>1	^h	>300 ^h	
28	>38	570 ± 215	5.0	1.9 ± 0.8	390 ± 40	3.5 ± 0.7
7 ^j	7.9 ^k	563 ± 52	37 000	50 ± 11	225 ± 30	3.6
29 ^l		694 ± 122	800	330 ± 110	30	1.7

^a Solubility (mM) in α -MEM culture medium containing 5% fetal calf serum, determined at ambient temperature by UV spectroscopy. ^b IC₅₀ (μM) determined against aerobic AA8 cells as described in the text, using an exposure time of 18 h. Values are means ± SEM. ^c IC₅₀ ratio = IC₅₀(AA8)/IC₅₀(Walker cells). Walker cell IC₅₀ values were determined using continuous drug exposure under aerobic conditions for 4 days. Ratios are interexperiment means. ^d HF: hypersensitivity factor = IC₅₀(AA8)/IC₅₀(UV4), using an 18-h drug exposure under aerobic conditions for both lines. Values are intraexperiment means ± SEM. ^e CT₁₀: the product of the drug concentration (μM) and exposure time (h) required to reduce cell survival to 10% of that of controls under hypoxic conditions, using UV4 cells at 10⁶/mL in the clonogenic assay (see text). Mean ± SEM for separate cultures. ^f Ratio of CT₁₀ values in air and N₂ [CT₁₀(air)/CT₁₀(nitrogen)]. Mean ± SEM for separate experiments. ^g Some values taken from ref 17. ^h Inactive at solubility limit. ⁱ IC₅₀ > solubility limit in both lines. ^j Aziridine 7 (CB 1954). ^k Solubility in water, taken from ref 40. ^l Aziridine 29.

The hypoxic selectivities of these compounds also varied widely (from 1.3- to 60-fold) in UV4 cell cultures. As reported previously,¹⁷ the parent mustard 6 shows much higher selectivity than the corresponding aziridine 7. The cationic analogues 11 and 12 retained the high selectivity of 6 for hypoxic cells, but the other readily soluble compounds (13, 14, and 16) showed lower selectivity.

The second series of compounds studied (17–28) explored the effects of more extensive changes in structure, primarily altering mustard reactivity (by changing either the leaving group or the electronic properties of the side-chain substituent). It is well known that the use of better leaving groups on the mustard increases alkylating potency, and we have shown this to be the case for the *in vitro* cytotoxicities of simple aniline mustards.¹⁴ In the present study, the bromo and iodo mustard derivatives 17 and 18 were about 10-fold more potent than 6 in both the growth inhibition and clonogenic assays, but this gain was essentially offset by a drop in solubility of similar magnitude. The low potency of the dimesylate 19 was unexpected, since this should be a more reactive species than the chloro mustard 6. Following a report²⁴ that mixed chloro/mesylate mustards show greater potency and higher solubility than the corresponding bischloro compounds, we prepared and evaluated the analogues compound 20. This proved to be about 4-fold more soluble than the dichloro analogue 6 and twice as potent in hypoxic UV4 cultures, with equivalent hypoxic selectivity.

The nitrile derivative 22 was 20-fold more potent than 6 in the growth inhibition assay, with little loss in solubility, but had considerably lower hypoxic selectivity. The high potency of this compound is unexpected, given the strong electron-withdrawing effects of the nitrile group. The

thioamide 23 proved very insoluble, so that full biological data could not be obtained. The sulfonamide 24 was of particular interest, since this group is both more hydrophilic and more electron-withdrawing than a carboxamide.³¹ However, although 24 had only similar aqueous solubility to 6 and surprisingly poor hypoxic selectivity (which was not attributable to enhanced reduction by DT-diaphorase), it was extremely cytotoxic (by far the most potent of all the compounds studied). This potency is very sensitive to cell density, being substantially reduced at 2 × 10⁶ cells/mL (a property not shared by other members of the series). The related *N*-(methylsulfonyl)-benzenesulfonamide 25 was much more soluble, due to the ionizable NH group, but lost potency and did not regain hypoxic selectivity. The mono(2-chloroethyl)amine analogues 26–28 showed similar potencies to those of the corresponding full mustards against AA8 cells. Only 28 was sufficiently soluble to evaluate in the clonogenic assay; its selectivity (3.5-fold) was similar to that of CB 1954 (7).

The relative sensitivity of the compounds to reductive activation by DT-diaphorase was evaluated by determining the ratios of their IC₅₀s against the AA8 and Walker cell lines. The latter is very sensitive to 7, as shown by the AA8/Walker IC₅₀ differential of 37 000-fold. It also showed high (but lesser) sensitivity to 29, the only other aziridine tested. In contrast, the mustard analogues of these aziridines (6 and 10) showed ratios close to unity, suggesting they are much less efficient substrates for the Walker cell DT-diaphorase. The mono(2-chloroethyl)amine analogues with an *N*-ethyl group replacing the second *N*-2-chloroethyl function (27 and 28) also did not show significant selectivity for Walker cells, although 27 was not sufficiently




Figure 1. Reduction of dinitrobenzenecarboxamides (0.08 mM) by purified rat (Walker cell) DT-diaphorase (10 IU/mL) with 1.6 mM NADH under aerobic conditions in sodium phosphate buffer, pH 7.0, 20 °C. Concentrations of the parent nitro compounds (○, 7; ●, 29; □, 26; △, 11; ▲, 12) were monitored by HPLC.

soluble to determine its potency in the AA8 cell line. The secondary amine with a single 2-chloroethyl function (26) was 380-fold more toxic against Walker cells than AA8 cells. The intermediate sensitivity of Walker cells to 26 suggests that the steric effect of the bis(2-chloroethyl) substitution of 6 is responsible for inhibition of 2-electron reduction by DT-diaphorase.

Factors other than reduction by DT-diaphorase may influence the relative sensitivities of Walker and AA8 cells to nitro compounds. Rates of reduction by highly purified DT-diaphorase from Walker cells were therefore compared for a subset of compounds (Figure 1). We have previously shown¹⁷ that 6 is reduced by the purified enzyme at a rate at least 100-fold slower than is the corresponding aziridine 7. In the present work, 7 was again used as a standard for evaluating the rates of reduction of selected compounds of Table 1 (Figure 1). The only other compound to show appreciable reduction by the enzyme was the other aziridine (29); the half-mustard 26 was not reduced significantly (Figure 1). These results parallel the sensitivities of Walker cells to these agents (7 > 29 > 26; Table 2). The two full mustards 11 and 12 were also not reduced by the purified enzyme, consistent with the low sensitivity of Walker cells to these compounds.

On the basis of the sensitivity of Walker cells, none of the nitrophenyl mustards 6–25 are activated appreciably by DT-diaphorase. While there may be some species differences in DT-diaphorase substrate specificity, as demonstrated³² for 7, it appears unlikely that the large differences in hypoxic selectivity observed in UV4 cultures (1.3–60-fold) are due to variations in sensitivity to aerobic nitroreduction by this enzyme.

The hypersensitivity of UV4 cells to CB 1954 (7; HF value = 50) was in the range (8–200-fold) expected for DNA cross-linking agents, consistent with its proposed mechanism of toxicity.^{20,29} In contrast, almost all of the dinitrophenyl mustards gave HF values <8 (e.g., 3.9 ± 0.7 for 11), suggesting that DNA cross-links may not be responsible for the aerobic toxicity of these compounds. However, rates of killing by 11 under hypoxic conditions by clonogenic assay indicated an 18-fold greater sensitivity of UV4 than AA8 cells (CT₁₀ 375 ± 34 µM h for AA8 versus 21 ± 4 for UV4), consistent with activation of 11 to a DNA cross-linking agent under hypoxic conditions.




Figure 2. Demonstration of DNA interstrand cross-links in UV4 cells treated with 11 for 5 h under hypoxic conditions. [¹⁴C]-TdR-labeled cells received no drug treatment (○, ●) or were treated with 11 at 20 µM (□, ■), 100 µM (△, ▲), or 500 µM (od, sd) before assaying by alkaline elution. Filled symbols represent samples which received cobalt-60 irradiation (3 Gy) immediately before elution. The abscissa indicates retention of irradiated (3 Gy) [³H]TdR-labeled cells used as internal standard.

The ability of 11 to generate DNA interstrand cross-links in hypoxic AA8 cells was tested more directly using alkaline elution (Figure 2). Treatment with 11 at 500 µM for 5 h resulted in DNA breakage as demonstrated by an increased elution rate, although no breakage was observed at ≤100 µM. Treatment with 11 markedly retarded elution of irradiated DNA, providing clear evidence for concentration-dependent DNA cross-linking. Thus, despite the low HF value for this compound under aerobic conditions, it does act as a DNA cross-linking agent after reductive activation under hypoxia.

Overall, 11 was the best of the analogues evaluated with respect to solubility, potency, and hypoxic cell selectivity *in vitro* and was therefore evaluated *in vivo*. The maximum tolerated dose (MTD) of 11 in C₃H/HeN mice was 240 µmol/kg when given as a single ip injection. Figure 3 shows the effect of 11 on KHT tumors, assayed by excision and clonogenic assay 18 h after treatment, when administered alone or 5 min after γ-irradiation (15 Gy). It caused substantial tumor cell killing only at doses above the MTD. Killing due to the drug was about 5-fold greater in combination with radiation than for the drug alone, suggesting some selectivity for hypoxic cells, although this difference was not statistically significant. Cell killing by 11 in the absence of radiation indicates activity against oxygenated as well as hypoxic cells. We are currently investigating whether this reflects efficient release of a diffusible activated mustard from hypoxic microenvironments or whether the observed cell killing is independent of tumor hypoxia.

Conclusions

This work sought to identify analogues of the novel HSC 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (6) which retained its high selectivity for hypoxic cells *in vitro* but had increased potency and/or aqueous solubility. To this end, the composition of the carboxamide chain (compounds 8–16) or the reactivity of the mustard (compounds 17–25) was varied. The aqueous solubilities




Figure 3. Activity of 11 against KHT tumors in C₃H/HeN mice. The drug was administered ip alone (O) or 5 min after irradiation (●; 15 Gy, ⁶⁰Co). The ordinate is the product of cell yield/g of tumor and plating efficiency, determined 18 h after treatment. Points are geometrical means, and error bars are SEM for two to four separate experiments, each experiment using two to four pooled tumors per dose. The upper and lower hatched bands represent the 95% confidence limits for historical control data for untreated tumors and non-drug-treated irradiated tumors, respectively.

of the compounds studied were broadly predictable from structure, with ionizable or very dipolar groups providing the most soluble analogues (e.g., 11–14, 21, and 25). The neutral diol 16 also had acceptable solubility. However, many of these solubilizing groups also lowered cytotoxic potency. The hypoxic cell selectivity of the compounds varied markedly. No general structure–activity relationships for hypoxic selectivity could be discerned.

Despite marked variations in hypoxic selectivities, the mustard compounds all appeared to be poor substrates for Walker cell DT-diaphorase, with IC₅₀(AA8)/IC₅₀-(Walker) ratios of 1.5–6-fold [compared with 37 000 for 7, 800 for the dinitroaziridine 29, and 380 for the mono(2-chloroethyl)amine 26]. The lack of sensitivity of the mustards to reduction by DT-diaphorase, at least in rat Walker cells, is conceptually a desirable feature of these compounds, relative to the (dinitrophenyl)aziridines, in the context of their development as HSCs. However, it appears that this factor alone cannot account for the large differences in hypoxic selectivity observed within the dinitrophenyl mustard series. The low efficiency of DT-diaphorase in reducing nitro compounds, relative to quinones, quinoneimines, and nitroso compounds,^{32–34} makes it unclear whether this enzyme contributes significantly to the aerobic activation of 7 in other than rat cells. The hypoxic selectivity of quinone bioreductive drugs is markedly influenced by their susceptibility to reductive activation by DT-diaphorase,³⁵ but for nitro compounds, the contribution of toxicity from non-bioreductive mechanisms may be a more important determinant.³⁶ Although not systematically investigated in the present study, the apparently lower UV4 HF factor for 11 under aerobic conditions compared to that under hypoxic conditions suggests that a non-bioreductive mechanism of toxicity quite distinct from cross-link formation may contribute to aerobic toxicity. It is possible that this

phenomenon (rather than oxygen-insensitive bioreduction) might be responsible for the observed variations in hypoxic selectivity.

Compound 11 showed the best *in vitro* profile of the analogues evaluated and was active against KHT tumors in mice when given as a single dose (Figure 3). However, activity was seen only at doses which would eventually be lethal to the host, and the similarity of effect with and without radiation makes it unclear whether its (limited) activity *in vivo* is dependent on bioreduction. Thus, despite the favorable biological profile of 11 in cell culture, there remains a clear need for analogues with higher therapeutic ratios *in vivo*.

Experimental Section

Chemistry. Analyses indicated by symbols of the elements were within ±0.4% of theoretical and were carried out in the Microchemical Laboratory, University of Otago, Dunedin, NZ. Melting points were determined on an Electrothermal 2300 melting point apparatus. NMR spectra were obtained on Bruker AC-200 or AM-400 spectrometers and are referenced to Me₄Si. Thin-layer chromatography was carried out on aluminum-backed silica gel plates (Merck 60 F₂₅₄). Flash column chromatography was carried out on Merck silica gel (230–400 mesh). Petroleum ether refers to the fraction boiling at 40–60 °C. All compounds were checked for purity by reverse-phase HPLC with diode array detection.

5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzoic Acid (21) and Derivatives. Methyl 5-chloro-2,4-dinitrobenzoate²¹ (30) (1.24 g, 4.76 mmol) was treated with diethanolamine (1.00 g, 9.52 mmol) in dioxane (50 mL) at 50 °C for 3 h, and the residue after workup was chromatographed on silica gel. Elution with EtOAc gave methyl 5-[*N,N*-bis(2-hydroxyethyl)amino]-2,4-dinitrobenzoate (31) (1.52 g, 97%), mp (EtOAc/petroleum ether) 104–106 °C. ¹H NMR (CDCl₃): δ 8.48 (s, 1 H, H-3), 7.45 (s, 1 H, H-6), 3.95 (s, 3 H, OCH₃), 3.81 (t, *J* = 5.0 Hz, 4 H, CH₂OH), 3.60 (t, *J* = 5.0 Hz, 4 H, CH₂N), 2.20 (br, 2 H, OH). ¹³C NMR: δ 165.89 (COOMe), 147.53 (C-5), 138.67, 136.21 (C-2,4), 133.30 (C-1), 124.22, 121.65 (C-3,6), 59.34 (CH₂OH), 54.59 (CH₂N), 53.74 (OCH₃). Anal. (C₁₂H₁₅N₃O₈) C, H, N.

A solution of 31 (1.50 g, 4.56 mmol) and Et₃N (1.33 mL, 9.57 mmol) in dry CH₂Cl₂ (60 mL) was treated with MsCl (0.73 mL, 9.34 mmol) at 0 °C and poured into saturated aqueous NaHCO₃ after 15 min. Dilution with CH₂Cl₂ and workup gave crude dimethylsulfate, which was treated directly with LiCl (10.0 g) in DMF (40 mL) at 120 °C for 30 min. The mixture was poured into brine, extracted with EtOAc, worked up, dried over Na₂SO₄, and chromatographed on silica gel. Elution with EtOAc/petroleum ether (4:1) gave methyl 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzoate (33) (1.34 g, 80%), mp (EtOAc/petroleum ether) 136.5–138 °C. ¹H NMR (CDCl₃): δ 8.54 (s, 1 H, H-3), 7.34 (s, 1 H, H-6), 3.97 (s, 3 H, OCH₃), 3.68 (br s, 8 H, NCH₂CH₂Cl). ¹³C NMR: δ 165.30 (COOCH₃), 147.22 (C-5), 139.81, 137.82 (C-2,4), 133.39 (C-1), 124.33, 121.77 (C-3,6), 53.86 (OCH₃), 53.78 (CH₂N), 40.69 (CH₂Cl). Anal. (C₁₂H₁₃Cl₂N₃O₆) C, H, N, Cl.

Hydrolysis of 33 (4.51 g, 12 mmol) with 4 N KOH (20 mL) in dioxane (60 mL) at 20 °C for 15 min followed by acidification with 3 N HCl and extraction with EtOAc gave a quantitative yield of 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzoic acid (21), mp (EtOAc/petroleum ether) 125–127 °C. ¹H NMR [(CD₃)₂CO]: δ 8.56 (s, 1 H, H-3), 7.72 (s, 1 H, H-6), 3.89–3.86 (br, 8 H, NCH₂CH₂Cl) (COOH too broad to observe). ¹³C NMR: δ 166.02 (COOH), 148.52 (C-5), 140.25, 138.09 (C-2,4), 134.72 (C-1), 124.87, 122.58 (C-3,6), 54.12 (CH₂N), 42.12 (CH₂Cl). Anal. (C₁₁H₁₁Cl₂N₃O₆·1/2EtOAc) C, H, N, Cl (signals for 1/2EtOAc seen in ¹H and ¹³C NMR spectra).

Heating of 21 (0.40 g, 1.14 mmol) in SOCl₂ (20 mL) containing a drop of DMF under reflux for 20 min followed by concentration to dryness and azeotropeing with benzene gave crude 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzoyl chloride, which was dissolved in Me₂CO (20 mL), cooled to 0 °C, and treated with excess aqueous methylamine (10 mL of a 40% solution in water). After 15 min, the mixture was extracted with EtOAc, and the

product after workup was purified by chromatography on silica gel. Elution with EtOAc/petroleum ether (1:1) gave 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-methyl-2,4-dinitrobenzamide (8) (0.31 g, 75%), mp (EtOAc/petroleum ether) 180.5 °C. ¹H NMR [(CD₃)₂CO]: δ 8.53 (s, 1 H, H-3), 7.75 (br, 1 H, CONH), 7.56 (s, 1 H, H-6), 3.88–3.80 (m, 8 H, NCH₂CH₂Cl), 2.90, 2.89 (2 s, 3 H, CONHMe). ¹³C NMR: δ 165.89 (CONH), 148.43 (C-5), 140.05, 138.26 (C-2,4), 138.94 (C-1), 125.05, 122.45 (C-3,6), 54.20 (CH₂N), 42.10 (CH₂Cl), 26.69 (CONHCH₃). Anal. (C₁₂H₁₄Cl₂N₄O₅) C, H, N, Cl.

Similar treatment of the acid chloride with the appropriate amines gave the following compounds:

5-[*N,N*-Bis(2-chloroethyl)amino]-*N,N*-dimethyl-2,4-dinitrobenzamide (9) (65% yield), mp (CHCl₃/petroleum ether) 130.5 °C. ¹H NMR (CDCl₃): δ 8.61 (s, 1 H, H-3), 7.07 (s, 1 H, H-6), 3.62 (s, 8 H, NCH₂CH₂Cl), 3.07, 2.78 (2 × 3 H, CON(CH₃)₂). ¹³C NMR: δ 166.12 (CON(CH₃)₂), 148.33 (C-5), 138.88, 135.75 (C-2,4), 137.82 (C-1), 124.92, 120.00 (C-3,6), 53.55 (CH₂N), 40.98 (CH₂Cl), 38.06, 34.85 (CON(CH₃)₂). Anal. (C₁₃H₁₆Cl₂N₄O₅) C, H, N.

5-[*N,N*-Bis(2-chloroethyl)amino]-*N*-[2-(4-morpholino)ethyl]-2,4-dinitrobenzamide (12) (72% yield) as a gum. The hydrochloride salt crystallized from MeOH/ⁱPr₂O, mp 119–120 °C. ¹H NMR (D₂O): δ 8.81 (s, 1 H, H-3), 7.59 (s, 1 H, H-6), 4.07 (br, NH and HCl), 3.91 (t, *J* = 6.0 Hz, 4 H, N⁺CH₂CH₂O), 3.86–3.81 (m, 10 H, NCH₂CH₂Cl and CH₂CH₂N⁺), 3.56 (t, *J* = 6.0 Hz, 6 H, N⁺CH₂CH₂O and CONHCH₂). ¹³C NMR: δ 171.17 (CONH), 151.69 (C-5), 140.61, 137.28 (C-2,4), 138.12 (C-1), 128.53, 123.48 (C-3,6), 66.30 (N⁺CH₂CH₂O), 58.07 (CH₂N⁺), 55.48 (CH₂N), 54.65 (N⁺CH₂CH₂O), 44.09 (CH₂Cl), 36.84 (CONHCH₂). Anal. (C₁₇H₂₃Cl₂N₅O₆·HCl·0.5H₂O) C, H, N, Cl.

5-[*N,N*-Bis(2-chloroethyl)amino]-*N*-(2-hydroxyethyl)-2,4-dinitrobenzamide (15) (85% yield), mp (EtOAc/petroleum ether) 157–158 °C. ¹H NMR [(CD₃)₂SO]: δ 8.73 (t, *J* = 5.5 Hz, 1 H, CONH), 8.53 (s, 1 H, H-3), 7.45 (s, 1 H, H-6), 4.76 (t, *J* = 5.5 Hz, 1 H, OH), 3.82 (t, *J* = 6.0 Hz, 4 H, CH₂Cl), 3.68 (t, *J* = 6.0 Hz, 4 H, CH₂N), 3.54 (dt, *J* = 6.1, 5.5 Hz, 2 H, CH₂OH), 3.31 (dt, *J* = 6.1, 5.5 Hz, 2 H, CONHCH₂). ¹³C NMR: δ 164.44 (CONH), 147.11 (C-5), 137.87, 136.27 (C-2,4), 137.32 (C-1), 124.24, 121.01 (C-3,6), 59.32 (CH₂OH), 52.44 (CH₂N), 41.93 (CONHCH₂), 41.65 (CH₂Cl). Anal. (C₁₃H₁₆Cl₂N₂O₆) C, H, N, Cl.

5-[*N,N*-Bis(2-chloroethyl)amino]-*N*-(2,3-dihydroxypropyl)-2,4-dinitrobenzamide (16) (59% yield) as a hygroscopic yellow foam. ¹H NMR [(CD₃)₂SO]: δ 8.70 (t, *J* = 5.7 Hz, 1 H, CONH), 8.53 (s, 1 H, H-3), 7.44 (s, 1 H, H-6), 4.83 (d, *J* = 4.9 Hz, 1 H, CHOH), 4.56 (t, *J* = 5.7 Hz, 1 H, CH₂OH), 3.83 (t, *J* = 5.9 Hz, 4 H, CH₂Cl), 3.68 (t, *J* = 5.9 Hz, 4 H, CH₂N), 3.50–3.06 (m, 5 H, CONHCH₂CHOHCH₂OH). ¹³C NMR: δ 164.61 (CONH), 147.12 (C-5), 37.94, 136.40 (C-2,4), 137.40 (C-1), 124.29, 121.18 (C-3,6), 70.08 (CHOH), 63.77 (CH₂OH), 52.55 (CH₂N), 42.79 (CONHCH₂), 41.72 (CH₂Cl). Anal. (C₁₄H₁₈Cl₂N₄O₇) C, H, Cl, N; calcd, 12.6; found, 13.2.

5-[*N,N*-Bis(2-chloroethyl)amino]-*N*-(2-carboxyethyl)-2,4-dinitrobenzamide (14). Treatment of crude 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzoyl chloride (0.90 g, 2.50 mmol) in CH₂Cl₂ (20 mL) with a slurry of β-alanine methyl ester hydrochloride (0.70 g, 5.00 mmol) and Et₃N (1.04 mL, 7.50 mmol) in CH₂Cl₂ (20 mL) at 20 °C for 2 h gave crude 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-[2-(methoxycarbonyl)ethyl]-2,4-dinitrobenzamide as a yellow oil. This was immediately dissolved in THF (25 mL) and treated with aqueous KOH (10 mL of 2 N) at 20 °C for 3 h. The solution was then acidified with concentrated HCl, extracted with EtOAc, and worked up as usual. Chromatography on silica gel, eluting with EtOAc, gave 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-(2-carboxyethyl)-2,4-dinitrobenzamide (14) (0.72 g, 68%), mp (EtOAc/petroleum ether) 150–153 °C. ¹H NMR [(CD₃)₂SO]: δ 12.27 (br, 1 H, COOH), 8.79 (t, *J* = 5.6 Hz, 1 H, CONH), 8.54 (s, 1 H, H-3), 7.42 (s, 1 H, H-6), 3.83 (t, *J* = 6.0 Hz, 2 H, CH₂Cl), 3.68 (t, *J* = 6.0 Hz, 4 H, CH₂N), 3.44 (dt, *J* = 6.9, 5.6 Hz, 2 H, CONHCH₂), 2.53 (t, *J* = 6.9 Hz, 2 H, CH₂COOH). ¹³C NMR: δ 172.74 (COOH), 164.53 (CONH), 147.21 (C-5), 137.94, 136.13 (C-2,4), 137.29 (C-1), 124.37, 120.93 (C-3,6), 52.58 (CH₂N), 41.72 (CH₂Cl), 35.24, 33.19 (CONHCH₂CH₂). Anal. (C₁₄H₁₆Cl₂N₄O₇) C, H, N, Cl.

5-[*N,N*-Bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (19) and Analogues. MsCl (5.17 mL, 0.067 mol)

was added dropwise to a cooled (0 °C) solution of 5-[*N,N*-bis(2-hydroxyethyl)amino]-2,4-dinitrobenzamide (36)¹⁷ (10.00 g, 0.032 mol) in dry pyridine (150 mL). After a further 10 min at 0 °C, the solution was stirred at 20 °C for 30 min and then volatiles were removed under reduced pressure at below 40 °C. The residue was partitioned between EtOAc and water, and the organic layer was washed with water and worked up to give a low-melting solid which was chromatographed on silica gel. Elution with EtOAc gave foreruns followed by 5-[*N,N*-bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (19) (11.05 g, 74%), mp (EtOAc/petroleum ether; sealed tube) 140–144 °C. ¹H NMR [(CD₃)₂CO]: δ 8.54 (s, 1 H, H-3), 7.65 (s, 1 H, H-6), 4.49 (t, *J* = 5.3 Hz, 4 H, CH₂OSO₂CH₃), 3.89 (t, *J* = 5.3 Hz, 4 H, CH₂N), 3.09 (s, 6 H, SO₂CH₃), 2.90 (br s, NH₂). ¹³C NMR: δ 167.01 (CONH₂), 148.56 (C-5), 140.45, 138.44 (C-2,4), 138.57 (C-1), 124.92, 123.06 (C-3,6), 67.65 (CH₂OSO₂CH₃), 52.02 (CH₂N), 37.23 (SO₂CH₃). Anal. (C₁₃H₁₈N₄O₁₁S₂) C, H, N, S.

A solution of 19 (1.00 g, 2.12 mmol) in dry DMF (50 mL) was treated with solid NaBr (10.0 g), warmed to 120 °C with vigorous stirring for 15 min and then concentrated to dryness under reduced pressure. The residue was partitioned between EtOAc and water, and the organic portion was washed well with 3 N HCl and worked up. Chromatography of the residue on silica gel and elution with EtOAc/petroleum ether (1:1) gave 5-[*N,N*-bis(2-bromoethyl)amino]-2,4-dinitrobenzamide (17) (0.73 g, 78%), mp (EtOAc/petroleum ether) 126–128 °C. ¹H NMR [(CD₃)₂CO]: δ 8.53 (s, 1 H, H-3), 7.58 (s, 1 H, H-6), 3.89 (t, *J* = 6.6 Hz, 4 H, CH₂N), 3.73 (t, *J* = 6.6 Hz, 4 H, CH₂Br), 2.93 (br, 2 H, CONH₂). ¹³C NMR: δ 167.20 (CONH₂), 147.89 (C-5), 140.06, 138.26 (C-2,4), 138.75 (C-1), 124.95, 122.30 (C-3,6), 54.11 (CH₂N), 29.89 (CH₂Br). Anal. (C₁₁H₁₂Br₂N₄O₆) C, H, N. A similar reaction using NaI gave 5-[*N,N*-bis(2-iodoethyl)amino]-2,4-dinitrobenzamide (18) in 92% yield, mp (EtOAc/petroleum ether) 170–172 °C. ¹H NMR [(CD₃)₂CO]: δ 8.52 (s, 1 H, H-3), 7.55 (s, 1 H, H-6), 3.84 (t, *J* = 7.2 Hz, 4 H, CH₂N), 3.50 (t, *J* = 7.2 Hz, 4 H, CH₂I), 2.88 (br, 2 H, CONH₂). ¹³C NMR: δ 167.09 (CONH₂), 147.17 (C-5), 140.08, 138.33 (C-2,4), 138.74 (C-1), 124.94, 122.31 (C-3,6), 54.89 (CH₂N), 1.72 (CH₂I). Anal. (C₁₁H₁₂I₂N₄O₆) H, N, I; calcd, 24.7; found, 25.5; I: calcd, 47.5; found, 46.9.

5-[*N*-(2-Chloroethyl)-*N*-[2-[(methylsulfonyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (20). A solution of *tert*-butyldimethylsilyl chloride (1.00 g, 6.68 mmol) in DMF (10 mL) was added to a solution of 36 (1.00 g, 3.18 mmol) and imidazole (0.54 g, 7.95 mmol) in DMF (60 mL). After stirring at 20 °C for 18 h, the solution was concentrated to dryness under reduced pressure, the residue was partitioned between EtOAc and brine and worked up, and the oily residue was chromatographed on silica gel. After foreruns with EtOAc/petroleum ether (1:9), elution with EtOAc/petroleum ether (1:1) gave 5-[*N,N*-bis[2-[(*tert*-butyldimethylsilyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (39) (0.65 g, 38%), mp (EtOAc/petroleum ether) 127–129 °C. ¹H NMR (CDCl₃): δ 8.57 (s, 1 H, H-3), 7.26 (s, 1 H, H-6), 5.95, 5.65 (2 × br, 2 H, CONH₂), 3.79 (t, *J* = 5.4 Hz, 4 H, CH₂O), 3.51 (t, *J* = 5.4 Hz, 4 H, CH₂N), 0.82 (s, 18 H, Si(CH₃)₃), 0.00 (s, 12 H, Si(CH₃)₂). ¹³C NMR: δ 167.36 (CONH), 148.72 (C-5), 137.66 (C-2), 136.31 (C-1), 133.97 (C-4), 125.09 (C-3), 119.44 (C-6), 60.55 (CH₂O), 54.89 (CH₂N), 25.70 (C(CH₃)₃), 18.06 (C(CH₃)₃), -5.57 (SiCH₃). Anal. (C₂₃H₄₂N₄O₇Si₂·0.5H₂O) C, H, N.

Elution with EtOAc gave 5-[*N*-(2-hydroxyethyl)-*N*-[2-[(*tert*-butyldimethylsilyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (40) (0.60 g, 44%), mp (EtOAc/petroleum ether) 152–154 °C. ¹H NMR (CDCl₃): δ 8.53 (s, 1 H, H-3), 7.32 (s, 1 H, H-6), 6.27, 6.12 (2 × br, 2 H, CONH₂), 3.82 (br, 2 H, CH₂OH), 3.75 (t, *J* = 5.0 Hz, 2 H, CH₂OSi), 3.63 (t, *J* = 5.0 Hz, 2 H, CH₂N), 3.49 (t, *J* = 5.0 Hz, 2 H, CH₂N), 0.80 (s, 9 H, Si(CH₃)₃), -0.01 (s, 6 H, Si(CH₃)₂). ¹³C NMR: δ 167.69 (CONH), 148.37 (C-5), 138.09 (C-2), 136.44 (C-1), 134.59 (C-4), 124.85 (C-3), 120.46 (C-6), 60.40, 59.50 (CH₂O), 54.94, 54.60 (CH₂N), 25.67 (C(CH₃)₃), 18.09 (C(CH₃)₃), -5.65 (SiCH₃). Anal. (C₁₇H₂₈N₄O₇Si) C, H, N.

A solution of 40 (0.40 g, 0.93 mmol) and Et₃N (195 μL, 1.40 mmol) in CH₂Cl₂ (5 mL) was treated with MsCl (79 μL, 1.03 mmol) at 20 °C. After 10 min, the solution was washed with water and worked up, and the resulting crude mesylate (41) was dissolved in DMF (20 mL) containing LiCl (5.0 g) and heated to 125 °C for 20 min. Solvent was then removed under reduced pressure, the residue was partitioned between EtOAc and water,

and the organic residue was chromatographed on silica gel. Elution with EtOAc/MeOH (19:1) gave 5-[*N*-(2-chloroethyl)-*N*-(2-hydroxyethyl)amino]-2,4-dinitrobenzamide (42) (0.27 g, 87%) as a waxy solid. A solution of this crude product (0.40 g, 0.93 mmol) and Et₃N (175 μL, 1.21 mmol) in dry THF (10 mL) was treated with MsCl (69 μL, 0.89 mmol) for 10 min at 20 °C and then worked up as usual, and the residue was chromatographed on silica gel. Elution with EtOAc gave 5-[*N*-(2-chloroethyl)-*N*-[2-[(methylsulfonyl)oxy]ethyl]amino]-2,4-dinitrobenzamide (20) (0.26 g, 78%), mp (EtOAc/petroleum ether) 103–104.5 °C. ¹H NMR [(CD₃)₂SO]: δ 8.51 (s, 1 H, H-3), 8.13, 7.82 (2 × br, 2 H, CONH₂), 7.46 (s, 1 H, H-6), 4.33 (t, *J* = 5.0 Hz, 2 H, CH₂OMs), 3.81 (t, *J* = 6.0 Hz, 2 H, CH₂Cl), 3.72 (t, *J* = 5.0 Hz, 2 H, CH₂N), 3.64 (t, *J* = 6.0 Hz, 2 H, CH₂N), 3.12 (s, 3 H, SO₂CH₃). ¹³C NMR: δ 165.99 (CONH₂), 147.04 (C-5), 137.92, 137.47, 136.20 (C-1,2,4), 124.17, 120.84 (C-3,6), 66.70 (CH₂OMs), 52.90, 49.68 (CH₂N), 41.45 (CH₂Cl), 36.51 (SO₂CH₃). Anal. (C₁₂H₁₅ClN₄O₈S) C, H, N.

5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzotriole (22) and 5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrothiobenzamide (23). A solution of 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (6)¹⁷ (0.20 g, 0.57 mmol) in SOCl₂ (5 mL) was heated at reflux under N₂ for 84 h. Excess SOCl₂ was removed under reduced pressure, and the residue was chromatographed on silica gel. Elution with EtOAc/petroleum ether (3:7) gave 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzotriole (22) (0.16 g, 87%), mp (CHCl₃) 127 °C. ¹H NMR [(CD₃)₂CO]: δ 8.79 (s, 1 H, H-3), 8.19 (s, 1 H, H-6), 3.93 (s, 8 H, NCH₂CH₂Cl). ¹³C NMR: δ 148.55 (C-5), 140.98, 139.07 (C-2,4), 129.50, 126.10 (C-3,6), 115.05 (C-1), 112.84 (CN), 54.18 (CH₂N), 42.20 (CH₂Cl). Anal. (C₁₁H₁₀Cl₂N₄O₄) C, H, N.

A solution of 6 (0.50 g, 1.42 mmol) in dioxane (20 mL) was treated with P₂S₅ (0.63 g, 2.84 mmol) and NaHCO₃ (0.24 g, 2.84 mmol) and then heated under reflux with stirring for 3 h. The residue after workup was chromatographed on silica gel, and elution with EtOAc/petroleum ether (1:4) gave 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrothiobenzamide (23) (0.48 g, 92%), mp (EtOAc/petroleum ether) 166–167 °C. ¹H NMR [(CD₃)₂SO]: δ 9.50, 9.34 (2 × br, 2 H, CSNH₂), 8.50 (s, 1 H, H-3), 7.45 (s, 1 H, H-6), 3.87, 3.82 (2 × m, 8 H, NCH₂CH₂Cl). ¹³C NMR: δ 199.46 (CSNH₂), 148.08 (C-5), 143.87 (C-1), 139.51, 136.99 (C-2,4), 125.23, 121.36 (C-3,6), 54.23 (CH₂N), 42.02 (CH₂Cl). Anal. (C₁₁H₁₂Cl₂N₄O₄S) C, H, N, S.

5-[*N,N*-Bis(2-chloroethyl)amino]-*N*-[(*N,N*-dimethylamino)ethyl]-2,4-dinitrobenzamide *N*-Oxide (13). A solution of the free base of 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-[(*N,N*-dimethylamino)ethyl]-2,4-dinitrobenzamide (11)¹⁷ (0.50 g, 1.18 mmol) in CH₂Cl₂ (15 mL) was treated with a solution of 2-(phenylsulfonyl)-3-phenyloxaziridine²² (0.32 g, 1.24 mmol) in CH₂Cl₂ (3 mL). After 10 min, petroleum ether (10 mL) was added, the solution was cooled at –30 °C overnight, and the resulting solid was dried under high vacuum to give 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-[(*N,N*-dimethylamino)ethyl]-2,4-dinitrobenzamide *N*-oxide (13) as a hygroscopic foam. Treatment with MeOH/HCl gave the hydrochloride salt (0.36 g, 64%), mp (MeOH/¹Pr₂O) 165–169 °C. ¹H NMR [D₂O/(CD₃)₂SO]: δ 8.82 (s, 1 H, H-3), 7.46 (s, 1 H, H-6), 3.98, 3.93 (2 t, *J* = 5.1 Hz, 2 × 2 H, CH₂CH₂), 3.82 (t, *J* = 4.7 Hz, 4 H, CH₂Cl), 3.77 (t, *J* = 4.7 Hz, 4 H, CH₂N), 3.57 (s, 6 H, N(CH₃)₂). ¹³C NMR: δ 170.71 (CONH), 151.63 (C-5), 140.68, 137.31 (C-3,6), 69.20 (CH₂N(O)Me₂), 59.03 (N(O)Me₂), 55.40 (CH₂N), 44.06 (CH₂Cl), 36.45 (CONHCH₂). Anal. (C₁₅H₂₁Cl₂N₅O₆·HCl) C, H, N, Cl.

5-[*N,N*-Bis(2-chloroethyl)amino]-2,4-dinitrobenzenesulfonamide (24). A solution of 5-chloro-2,4-dinitrobenzenesulfonamide²³ (37) (1.55 g, 5.5 mmol) and diethanolamine (1.16 g, 11 mmol) in dioxane (100 mL) was held at 60 °C for 1.5 h and then adsorbed directly onto silica gel by concentration under reduced pressure. Chromatography on silica gel, eluting with EtOAc/MeOH (19:1) gave 5-[*N,N*-bis(2-hydroxyethyl)amino]-2,4-dinitrobenzenesulfonamide (38) (1.91 g, 99%), mp (EtOAc/petroleum ether) 138–139 °C. ¹H NMR [(CD₃)₂SO]: δ 8.53 (s, 1 H, H-3), 7.97 (s, 1 H, H-6), 7.93 (br s, 2 H, SO₂NH₂), 4.88 (t, *J* = 5.1 Hz, 2 H, OH), 3.65 (dt, *J* = 5.2, 5.1 Hz, 4 H, CH₂OH), 3.49 (t, *J* = 5.1 Hz, 4 H, NCH₂). ¹³C NMR: δ 146.84 (C-5), 140.53 (C-1), 136.84, 134.39 (C-2,4), 125.70 (C-3), 120.88 (C-6), 58.03 (CH₂OH), 54.27 (NCH₂). Anal. (C₁₀H₁₄N₄O₈S) C, H, N, S.

A stirred solution of 38 (1.90 g, 5.43 mmol) and Et₃N (1.90 mL, 14 mmol) in dry THF (60 mL) was treated dropwise at 0 °C with MsCl (0.89 mL, 11 mmol). After a further 15 min, the solution was diluted with EtOAc, washed well with water, and worked up to give the crude dimesylate. This was immediately dissolved in DMF (50 mL) containing LiCl (20 g) and the mixture stirred at 130 °C for 15 min before solvent was removed under reduced pressure. The residue was partitioned between EtOAc and water, and the organic layer was worked up and chromatographed on silica gel. Elution with EtOAc gave 5-[*N,N*-bis(2-chloroethyl)amino]-2,4-dinitrobenzenesulfonamide (24) (1.47 g, 64%), mp (EtOAc/petroleum ether) 153–154 °C. ¹H NMR [(CD₃)₂CO]: δ 8.54 (s, 1 H, H-3), 7.99 (br s, 2 H, SO₂NH₂), 7.91 (s, 1 H, H-6), 3.84 (t, *J* = 6.0 Hz, 4 H, CH₂Cl), 3.67 (t, *J* = 6.0 Hz, 4 H, CH₂N). ¹³C NMR: δ 146.13 (C-5), 140.64 (C-1), 138.86, 136.93 (C-2,4), 124.95, 121.77 (C-3,6), 52.48 (CH₂N), 41.62 (CH₂Cl). Anal. (C₁₀H₁₂Cl₂N₄S₂O₆) C, H, N, S.

Treatment of 38 with 4 equiv of MsCl and Et₃N in THF at 20 °C followed by reaction with LiCl as above gave 5-[*N,N*-bis(2-chloroethyl)amino]-*N*-(methylsulfonyl)-2,4-dinitrobenzenesulfonamide (25), mp (EtOAc/petroleum ether) 206–208 °C. ¹H NMR [(CD₃)₂SO]: δ 8.33 (s, 1 H, H-3), 7.87 (s, 1 H, H-6), 3.79 (t, *J* = 6.2 Hz, 4 H, CH₂Cl), 3.59 (t, *J* = 6.2 Hz, 4 H, CH₂N), 2.82 (s, 3 H, SO₂CH₃). ¹³C NMR: δ 144.14 (C-5), 142.39 (C-1), 139.66, 139.04 (C-2,4), 123.79, 122.78 (C-3,6), 53.05 (CH₂N), 43.02 (SO₂CH₃), 41.54 (CH₂Cl). Anal. (C₁₁H₁₄Cl₂N₄S₂O₆·0.5H₂O) C, H, N, S.

5-[*N*-(2-Chloroethyl)amino]-2,4-dinitrobenzamide (26). A mixture of 5-chloro-2,4-dinitrobenzamide²¹ (1.23 g, 5.01 mmol), 2-chloroethylamine hydrochloride (0.58 g, 5.01 mmol), and Et₃N (1.54 mL, 0.011 mmol) in THF (20 mL) was held at 40 °C for 6 h and then partitioned between water and EtOAc. The residue from workup of the organic layer was chromatographed on silica gel, EtOAc eluting 5-[*N*-(2-chloroethyl)amino]-2,4-dinitrobenzamide (26) (0.39 g, 27%), mp (EtOAc/petroleum ether) 225 °C. ¹H NMR [(CD₃)₂SO]: δ 8.93 (br s, 1 H, NH), 8.77 (s, 1 H, H-3), 8.13, 7.82 (2 × br s, 2 H, CONH₂), 7.20 (s, 1 H, H-6), 3.90 (m, 4 H, NCH₂CH₂Cl). ¹³C NMR: δ 166.30 (CONH₂), 147.00 (C-5), 139.86 (C-1), 133.23, 129.22 (C-2,4), 124.69, 114.35 (C-3,6), 44.05, 42.65 (NCH₂CH₂Cl). Anal. (C₉H₉ClN₂O₆) C, H, N.

5-[*N*-(2-Chloroethyl)-*N*-ethylamino]-2,4-dinitrobenzamide (27) and 5-[*N*-(2-Chloroethyl)-*N*-ethylamino]-*N*-[2-(dimethylamino)ethyl]-2,4-dinitrobenzamide (28). A mixture of methyl 5-chloro-2,4-dinitrobenzoate (30)²¹ (3.39 g, 12 mmol) and *N*-ethylethanolamine (2.85 g, 32 mmol) in dioxane (20 mL) was kept at 20 °C for 8 h and then diluted with water. The resulting solid was chromatographed on silica gel, and elution with CH₂Cl₂/EtOAc (2:1) gave methyl 2,4-dinitro-5-[*N*-(2-hydroxyethyl)-*N*-ethylamino]benzoate (32) (3.64 g, 89%), mp (MeOH/H₂O) 87 °C. ¹H NMR (CDCl₃): δ 8.54 (s, 1 H, H-3), 7.26 (s, 1 H, H-6), 3.95 (s, 3 H, COOCH₃), 3.82 (t, *J* = 5.2 Hz, 2 H, CH₂OH), 3.56 (t, *J* = 5.2 Hz, 2 H, NCH₂CH₂), 3.35 (q, *J* = 7.1 Hz, 2 H, NCH₂CH₃), 1.95 (br s, 1 H, OH), 1.23 (t, *J* = 7.1 Hz, 3 H, CH₃). Anal. (C₁₂H₁₅N₃O₇) C, H, N. A stirred solution of 32 (3.76 g, 12 mmol) and Et₃N (1.93 mL, 14 mmol) in CH₂Cl₂ (20 mL) was treated dropwise at 0 °C with MsCl (1.09 mL, 14 mmol). The reaction mixture was stirred at 20 °C for a further 30 min and then diluted with CH₂Cl₂ (20 mL) and worked up to give the crude mesylate, which was dissolved in dry DMF (15 mL) and treated with LiCl (1.5 g, 35 mmol) at 80 °C for 15 min. Solvent was removed under reduced pressure, and the residue was partitioned between CH₂Cl₂ and dilute aqueous KHCO₃. The organic layer was washed with water, and the residue obtained after removal of the solvent was extracted with boiling petroleum ether to give methyl 5-[*N*-(2-chloroethyl)-*N*-ethylamino]-2,4-dinitrobenzoate (34) (3.26 g, 82%), mp (benzene/petroleum ether) 77–77.5 °C. ¹H NMR (CDCl₃): δ 8.52 (s, 1 H, H-3), 7.20 (s, 1 H, H-6), 3.97 (s, 3 H, COOCH₃), 3.65 (t, *J* = 5.9 Hz, 2 H, NCH₂CH₂), 3.59 (t, *J* = 5.9 Hz, 2 H, CH₂Cl), 3.45 (q, *J* = 7.1 Hz, 2 H, NCH₂CH₃), 1.23 (t, *J* = 7.1 Hz, 3 H, CH₃). Anal. (C₁₂H₁₄ClN₃O₆) C, H, N, Cl.

A solution of 34 in MeOH was treated with aqueous NaOH (1.5 equiv) and heated under reflux for 1 h and then diluted with water and acidified with HCl to give 5-[*N*-(2-chloroethyl)-*N*-ethylamino]-2,4-dinitrobenzoic acid (35) (88%), mp (benzene) 139.5–140.5 °C (light-sensitive). ¹H NMR [(CD₃)₂SO]: δ 14.10

(s, 1 H, COOH), 8.53 (s, 1 H, H-3), 7.51 (s, 1 H, H-6), 3.81 (t, $J = 6.2$ Hz, 2 H, NCH_2CH_2), 3.64 (t, $J = 6.2$ Hz, 2 H, CH_2Cl), 3.42 (q, $J = 7.1$ Hz, 2 H, NCH_2CH_3), 1.94 (t, $J = 7.1$ Hz, 3 H, CH_3). Anal. ($\text{C}_{11}\text{H}_{12}\text{ClN}_3\text{O}_6$) C, H, N, Cl. Treatment of this acid with SOCl_2/DMF followed by removal of excess reagent and azeotrope with benzene gave the crude acid chloride, which was dissolved in cold, dry Me_2CO and treated with excess concentrated ammonia to give 5-[*N*-(2-chloroethyl)-*N*-ethylamino]-2,4-dinitrobenzamide (27) (71% yield), mp (benzene) 151–152 °C. ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ 8.53 (s, 1 H, H-3), 8.10, 7.78 (2 × s, 2 H, CONH_2), 7.40 (s, 1 H, H-6), 3.82 (t, $J = 6.3$ Hz, 2 H, NCH_2CH_2), 3.64 (t, $J = 6.3$ Hz, 2 H, CH_2Cl), 3.39 (q, $J = 7.1$ Hz, 2 H, NCH_2CH_3), 1.13 (t, $J = 7.1$ Hz, 3 H, CH_3). Anal. ($\text{C}_{11}\text{H}_{13}\text{ClN}_4\text{O}_6$) C, H, N, Cl.

Similar treatment of the acid chloride with a solution of excess *N,N*-dimethylethylenediamine in CH_2Cl_2 followed by chromatography of the product on alumina (activity II–III) and elution with EtOAc gave 5-[*N*-(2-chloroethyl)-*N*-ethylamino]-*N*-[2-(dimethylamino)ethyl]-2,4-dinitrobenzamide (28) as an oil (77% yield). ^1H NMR (CDCl_3): δ 8.61 (s, 1 H, H-3), 7.13 (s, 1 H, H-6), 6.50 (br s, 1 H, CONH), 3.5–3.7 (3 × m, 3 × 2 H, $\text{NCH}_2\text{CH}_2\text{Cl}$ and CONHCH_2), 3.42 (q, $J = 7.1$ Hz, 2 H, NCH_2CH_3), 2.55 (t, $J = 5.9$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$), 2.24 (s, 6 H, $\text{N}(\text{CH}_3)_2$), 1.25 (t, $J = 7.1$ Hz, 3 H, NCH_2CH_3). The hydrochloride salt crystallized from EtOAc as yellow needles, mp 133–134 °C. Anal. ($\text{C}_{15}\text{H}_{22}\text{ClN}_5\text{O}_5\cdot\text{HCl}$) C, H, N, Cl.

Formulation of Compounds for Testing. The purity of all compounds was evaluated by HPLC with diode array absorbance detection. All had a purity of >97%, based on absorbance at 250 nm (bandwidth 80 nm). Stock solutions were prepared in α -MEM culture medium containing 5% fetal bovine serum and filter sterilized (11–14, 16, 21, 25, and 28); all other compounds were dissolved in dimethyl sulfoxide and diluted at least 200-fold into cell cultures. Stock solutions were stored at –80 °C, and concentrations were determined in each experiment by spectrophotometry in 0.01 N HCl. Compound 11 was dissolved in phosphate-buffered saline for administration to mice.

Rates of Reduction by Rat DT-Diaphorase. Reduction of selected compounds by highly purified DT-diaphorase (NAD(P)H:quinone oxidoreductase) from Walker cells¹⁹ was assessed by monitoring loss of parent compound by HPLC, essentially as described previously.¹⁷ Drugs (0.08 mM) were incubated with enzyme [10 IU; determined at 20 °C using menadione as substrate and cytochrome *c* ($\epsilon_{550} = 29\,500\text{ M}^{-1}\text{ cm}^{-1}$) as terminal electron acceptor] and NADH (1.6 mM) in 0.1 M sodium phosphate buffer at 20 °C under aerobic conditions in reaction volumes of 0.3 mL. Aliquots were removed at intervals and analyzed by HPLC, using direct injection onto a C18 μ Bondapak column (8 × 100 mm). The mobile phase for compounds 9, 26, and 29 was a linear gradient of MeOH and water and for 11 and 12 a linear gradient of formate buffer (pH 4.5) and acetonitrile. The eluate was monitored by diode array absorbance spectrophotometry.

Microculture Assays for Aerobic Growth Inhibition. AA8 or UV4 cell cultures¹⁷ were initiated in 96-well microtiter trays to give 200 (AA8) or 300 (UV4) cells in 0.05 mL per well. After growth in a CO_2 incubator for 24 h, drugs were added in culture medium, using serial 2-fold dilutions to provide duplicate cultures at five different concentrations for each of eight drugs (plus eight controls) per tray. After 18 h, drugs were removed by washing cultures three times with fresh medium, and the trays were incubated for a further 78 h. Cell density was then determined by staining with methylene blue, as described previously.³⁷ The IC_{50} was calculated as the drug concentration providing 50% inhibition of growth relative to the controls. The alkylating agent-sensitive (WS) Walker 256 adenocarcinoma cell line was obtained from Dr. Richard Knox, Institute of Cancer Research, Sutton, U.K. Inhibition of the growth of this cell line was determined as for AA8, except that the seeding cell density was 225 cells/0.15 mL, drug exposure was continuous throughout the growth period of 4 days, and cell densities were assessed using the MTT method.³⁸

Determination of Hypoxia-Selective Cytotoxicity in Vitro. Clonogenic assays with magnetically stirred 10-mL suspension cultures (late log-phase UV4 cells, $10^6/\text{mL}$) were performed by removing samples periodically during continuous gassing with 5% CO_2 in air or N_2 , as detailed elsewhere.²⁶ Both

cell suspensions and drug solutions in growth medium were pre-equilibrated under the appropriate gas phase for 60 min prior to mixing, to ensure essentially complete anoxia throughout the period of drug contact in hypoxic cultures. Several drug concentrations were investigated to identify those concentrations which gave, under both aerobic and hypoxic conditions, approximately the same rate of cell kill. The ratios of the concentration × time for a surviving fraction of 10% (CT_{10}) for these two survival curves were used as the measure of hypoxic selectivity.

Elution Assay for DNA Cross-Linking. AA8 cells were grown to $5 \times 10^6/\text{mL}$ and labeled with either [^{14}C]thymidine (TdR; 37 kBq/mL) or [^3H]TdR (3.7 kBq/mL) for 20 h. [^{14}C]TdR-labeled cells were exposed to 11 at 10^6 cells/mL for 5 h under hypoxic conditions as above and washed by centrifugation. An aliquot of 5×10^5 cells from each culture was irradiated on ice under aerobic conditions (3 Gy, cobalt-60), and cross-links were assayed using the method of Kohn et al.²³ with irradiated (3 Gy, cobalt-60) [^3H]TdR-labeled cells ($5 \times 10^6/\text{channel}$) as internal standard.

In Vivo Tumor Excision Assay. The maximum tolerated dose of 11 was estimated by treatment of groups of six male $\text{C}_3\text{H}/\text{HeN}$ mice with single ip doses (0.01 mL/g of body weight) at 1.5-fold dose intervals, with an observation time of 30 days. Groups of two mice bearing bilateral KHT tumors in the gastrocnemius muscle were treated with ip drug either alone or 5 min after whole body irradiation (cobalt 60, 15 Gy; ca. 2.5 Gy/min) of unanesthetized, unrestrained mice. Three to four tumors within the size range 0.5–1.0 mL at treatment were removed from each group 18 h later, pooled, and assayed for clonogenicity in agar essentially as described,³⁹ except that tumors were dissociated using an enzyme cocktail (0.5 mg/mL pronase, 0.2 mg/mL collagenase, 0.2 mg/mL DNase I) for 40 min and total nucleated cells were counted with an electronic particle counter.

Acknowledgment. This work was supported by contract CM 07321 from the US National Cancer Institute, by the Auckland Division of the Cancer Society of New Zealand, and by the Health Research Council of New Zealand. We thank Dr. Richard Knox, Institute of Cancer Research, Sutton, U.K., for a gift of purified rat Walker cell DT-diaphorase, Dr. Stephen Cliffe for assistance with the DT-diaphorase assays, Pierre van Zijl and Karin Tan for HPLC analyses, Susan Pullen for *in vitro* cytotoxicity testing, and John Moselen for the alkaline elution assay.

References

- Bush, R. S.; Jenkin, R. D. T.; Allt, W. E. C.; Beale, F. A.; Bean, H.; Dembo, A. J.; Pringle, J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. *Br. J. Cancer* 1978, 37, 302–306.
- Gatenby, R. A.; Kessler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 1988, 14, 831–838.
- Hockel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Baubmann, E.; Mitze, M.; Knapstein, P. G.; Vaupel, P. Intratumoral pO_2 predicts survival in advanced cancer of the uterine cervix. *Radiother. Oncol.* 1993, 26, 45–50.
- Wilson, W. R. Tumour hypoxia: challenges for cancer chemotherapy. In *Cancer Biology and Medicine*; Waring, M. J., Ponder, B. A. J., Eds.; Kluwer Academic Publishers: Lancaster, 1992; Vol. 3, pp 87–131.
- Rockwell, S.; Keyes, S. R.; Loomis, R.; Kelley, M.; Vyas, D. M.; Wong, H.; Doyle, T. W.; Sartorelli, A. C. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfomycin against hypoxic and oxygenated EMT6 carcinoma cells *in vitro* and *in vivo*. *Cancer Commun.* 1991, 3, 191–198.
- Hendriks, H. R.; Pizao, P. E.; Berger, D. P.; Kooistra, K. L.; Bibby, M. C.; Boven, E.; Dreefvan dermeulen, H. C.; Henrar, R. E. C.; Flebig, H. H.; Double, J. A.; Hornstra, H. W.; Pinedo, H. M.; Workman, P.; Schwartzmann, G. E09 - a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. *Eur. J. Cancer* 1993, 29A, 897–906.
- Sebolt-Leopold, J. S.; Elliot, W. L.; Showalter, H. D. H.; Leopold, W. R. Rationale for selection of PD 144872, the R-isomer of RB 6145, for clinical development as a radiosensitizer. *Proc. Am. Assoc. Cancer Res.* 1993, 34, 362.

- (8) Riley, R.; Hemingway, S. A.; Graham, M. A.; Workman, P. Initial characterization of the major mouse cytochrome-P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR-4233, WIN-59075). *Biochem. Pharmacol.* 1993, 45, 1065-1077.
- (9) Marshall, R. S.; Rauth, A. M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. *Cancer Res.* 1988, 48, 5655-5659.
- (10) Koch, C. J. Unusual oxygen dependence of toxicity of SR-4233, a hypoxic cell toxin. *Cancer Res.* 1993, 53, 3992-3997.
- (11) Wilson, W. R.; Moselen, J. W.; Cliffe, S.; Denny, W. A.; Ware, D. C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. *Int. J. Radiat. Oncol. Biol. Phys.*, in press.
- (12) Whillans, D. W.; Hunt, J. W. A rapid mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole. *Radiat. Res.* 1982, 90, 126-141.
- (13) Denny, W. A.; Wilson, W. R. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). *Cancer Met. Rev.* 1993, 12, 135-151.
- (14) Palmer, B. D.; Wilson, W. R.; Pullen, S. M.; Denny, W. A. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumour cells for substituted N,N-bis(2-chloroethyl) anilines. *J. Med. Chem.* 1990, 33, 112-121.
- (15) Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic mammalian cells. *J. Med. Chem.* 1986, 29, 879-887.
- (16) Panthanickal, A.; Hansch, C.; Leo, A. Structure-activity relationships in antitumor aniline mustards. *J. Med. Chem.* 1978, 21, 16-26.
- (17) Palmer, B. D.; Wilson, W. R.; Cliffe, S.; Denny, W. A. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. *J. Med. Chem.* 1992, 35, 3214-3222.
- (18) Wilson, W. R.; Palmer, B. D.; Pullen, S. M.; Cliffe, S.; Denny, W. A. SN 23862, an analogue of CB 1954 with decreased DT-diaphorase sensitivity and improved hypoxia-selective cytotoxicity. *40th Ann. Meeting Radiation Research Soc.* 1992, p 59, Abstract.
- (19) Knox, R. J.; Boland, M. P.; Friedlos, F.; Coles, B.; Southan, C.; Roberts, J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD-(P)H dehydrogenase (quinone) (EC 1.6.99.2). *Biochem. Pharmacol.* 1988, 37, 4671-4677.
- (20) Knox, R. J.; Friedlos, F.; Jarman, M.; Roberts, J. J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. *Biochem. Pharmacol.* 1988, 37, 4661-4667.
- (21) Goldstein, H.; Stamm, R. 4,6-Dinitro-3-chlorobenzoic acid. *Helv. Chim. Acta* 1952, 35, 1330-1332.
- (22) Davis, F. A.; Stringer, O. D. Chemistry of oxaziridines. 2. Improved synthesis of 2-sulfonyloxaziridines. *J. Org. Chem.* 1982, 47, 1774-1775.
- (23) Herbert, R. B.; Hollman, R. G. Phenazines. VI. The synthesis of some 2-aminophenazines and 2-aminocarboxyphenazinesulphonamides. *Tetrahedron* 1965, 21, 663-675.
- (24) Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Wilman, D. E. V. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). *Anti-Cancer Drug Des.* 1991, 6, 467-479.
- (25) Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 1. Relationship between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivative of nitracrine. *J. Med. Chem.* 1989, 32, 23-30.
- (26) Thompson, L. H.; Busch, H.; Brookman, K.; Mooney, C. L.; Glaser, D. A. Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. *Proc. Natl. Acad. Sci. U.S.A.* 1980, 78, 3734-3741.
- (27) Hoy, C. A.; Thompson, L. H.; Mooney, C. L.; Salazar, E. P. Defective DNA crosslink removal in Chinese hamster cell mutants sensitive to bifunctional alkylating agents. *Cancer Res.* 1985, 45, 1737-1747.
- (28) Kohn, K. W.; Ewigra, G.; Erickson, L. C.; Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In *DNA Repair. A Laboratory Manual of Research Procedures*; Friedberg, E., Hanawalt, P., Eds.; Marcel Dekker: New York, 1981; pp 379-401.
- (29) Roberts, J. J.; Friedlos, F.; Knox, R. J. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes as DNA interstrand crosslinker in Walker tumour cells. *Biochem. Biophys. Res. Commun.* 1986, 140, 1073-1078.
- (30) Whillans, D. W.; Rauth, A. M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. *Radiat. Res.* 1980, 34, 97-103.
- (31) Hansch, C.; Leo, A. *Substituent Constants for Correlation Analysis in Chemistry and Biology*; Wiley-Interscience: New York, 1979.
- (32) Boland, M. P.; Knox, R. J.; Roberts, J. J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). *Biochem. Pharmacol.* 1991, 41, 867-875.
- (33) Lind, C.; Cadenas, E.; Hochstein, P.; Ernster, L. DT-diaphorase: purification, properties and function. *Methods Enzymol.* 1990, 186, 287-301.
- (34) Horie, S. Advances in research on DT-diaphorase - catalytic properties, regulation of activity and significance in the detoxification of foreign compounds. *Kitasato Arch. Exp. Med.* 1990, 63, 11-30.
- (35) Plumb, J. A.; Thomson, P.; Workman, P. Marked sensitization to EO9 under hypoxic conditions in a cell line deficient in DT-diaphorase activity. *8th International Conference on Chemical Modifiers of Cancer Treatment*, 1993, p 63, Abstract.
- (36) Siim, B. G.; Atwell, G. J.; Wilson, W. R. Metabolic and radiolytic reduction of 4-alkylamino-5-nitroquinoline bioreductive drugs: relationship to selectivity for hypoxic cells. *Biochem. Pharmacol.*, in press.
- (37) Finlay, G. J.; Baguley, B. C.; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. *Anal. Biochem.* 1984, 139, 272-277.
- (38) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 1983, 65, 55-63.
- (39) Hill, R. P.; Gulyas, S.; Whitmore, G. F. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. *Br. J. Cancer* 1986, 53, 743-751.
- (40) Cobb, I. M.; Connors, T. A.; Elson, L. A.; Khan, A. H.; Micheley, B. C. V.; Ross, W. C. J.; Whisson, M. E. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954); a potent and selective inhibitor of the growth of the Walker carcinoma 256. *Biochem. Pharmacol.* 1969, 18, 1519-1527.